Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies

BACKGROUND: Most patients with chronic plaque psoriasis receive topical treatment; however, available options lack a balance of efficacy with long-term safety and tolerability. Roflumilast cream 0.3% is a highly potent phosphodiesterase 4 (PDE4) inhibitor approved by the US FDA for treatment of psor...

Descripción completa

Detalles Bibliográficos
Autores principales: Thurston, Archie W., Osborne, David W., Snyder, Scott, Higham, Robert C., Burnett, Patrick, Berk, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968262/
https://www.ncbi.nlm.nih.gov/pubmed/36422852
http://dx.doi.org/10.1007/s40257-022-00741-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968262/
https://www.ncbi.nlm.nih.gov/pubmed/36422852
http://dx.doi.org/10.1007/s40257-022-00741-9

Ejemplares similares